Market Place
Sourcing Support
Revolo`s Preclinical Data On Sublingual ‘1104 In Allergic Disease
21 Oct 2024 //
GLOBENEWSWIRE
Revolo Announces New Preclinical `1104 Data For Atopic Dermatitis
18 Sep 2024 //
GLOBENEWSWIRE
Revolo Announces Fireside Chat At Canaccord Genuity Growth Conference
07 Aug 2024 //
GLOBENEWSWIRE
Revolo`s New Data On `1104 Mechanism And Subcutaneous Admin
24 Jul 2024 //
GLOBENEWSWIRE
Revolo Biotherapeutics to Present at Upcoming Medical Meetings in May
14 May 2024 //
GLOBENEWSWIRE
Revolo Receives ODD from the U.S. FDA for its First-in-Class Peptide
30 Jan 2024 //
GLOBENEWSWIRE
Revolo Biotherapeutics Presents New Data on ˜1805 at Annual Conference
07 Nov 2023 //
GLOBENEWSWIRE
Revolo Biotherapeutics Announces Data from Study of˜1104 in Atopic Adults
25 Oct 2023 //
GLOBENEWSWIRE
Revolo to Present Data from Phase 2a Trial of ˜1104 in Eosinophilic Esophagitis
17 Oct 2023 //
GLOBENEWSWIRE
Revolo Announces the Completion of Phase 1 Ascending Dose Trial of ˜1104
21 Sep 2023 //
GLOBENEWSWIRE
Revolo Biotherapeutics to Host Virtual KOL Event on ˜1104
08 Aug 2023 //
GLOBENEWSWIRE
Revolo Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with EoE
18 Jul 2023 //
GLOBENEWSWIRE
Revolo Biotherapeutics Presents New Data for ˜1805 in Inflammatory Bowel Disease
05 Jun 2023 //
GLOBENEWSWIRE
Revolo Biotherapeutics Presents New Preclinical Data for 1104 at the ATS
22 May 2023 //
GLOBENEWSWIRE
Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings
10 May 2023 //
GLOBENEWSWIRE
Revolo Biotherapeutics Announces Positive Topline Data from Phase 2a Trial
19 Apr 2023 //
GLOBENEWSWIRE
Revolo drops dab of midphase data on would-be Dupixent rival
19 Apr 2023 //
FIERCE BIOTECH
Revolo Biotherapeutics to Present at the 8th Food Allergy Fund Summit
13 Apr 2023 //
GLOBENEWSWIRE
Revolo Announces Completion of Phase 2a Trial of 1104 in Allergic Disease
27 Mar 2023 //
GLOBENEWSWIRE
Revolo Presents New Data Demonstrating Long-Lasting Effect of 1104
28 Feb 2023 //
GLOBENEWSWIRE
Revolo to Present Recently Generated Data at the 2023 AAAAI Annual Meeting
06 Feb 2023 //
GLOBENEWSWIRE
Revolo Biotherapeutics Completes Enrollment in Ph 2 Trial
05 Jan 2023 //
GLOBENEWSWIRE
Revolo Biotherapeutics Announces That Last Patient in its Ph2a Trial of ‘1104
09 Nov 2022 //
GLOBENEWSWIRE
Revolo Completes Enrollment in Ph2 Trial of ‘1104 in Eosinophilic Esophagitis
12 Sep 2022 //
GLOBENEWSWIRE
Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings
16 May 2022 //
GLOBENEWSWIRE
Revolo Biotherapeutics to Lead Panel Discussion on Autoimmune Disease Treatment
10 May 2022 //
GLOBENEWSWIRE
Revolo to Participate in LifeSci Partners Immunology & Inflammation Symposium
05 May 2022 //
GLOBENEWSWIRE
Revolo Biotherapeutics to Participate at SVB Leerink Biopharma Pvt. Co. Connect
24 Mar 2022 //
GLOBENEWSWIRE
Revolo Biotherapeutics To Present New Data at 2022 AAAAI Annual Meeting
25 Feb 2022 //
GLOBENEWSWIRE
Revolo Bio Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805
04 Feb 2022 //
GLOBENEWSWIRE
Revolo activates clinical sites and begins enrollment in phase 2 trial of ‘1104
29 Oct 2021 //
PHARMABIZ
Revolo Biotherapeutics Activates Clinical Sites and Opens Enrollment in a Ph2
28 Oct 2021 //
GLOBENEWSWIRE
Revolo Biotherapeutics Activates Clinical Trial and Commences Enrollment in Ph2
21 Oct 2021 //
GLOBENEWSWIRE
Revolo Biotherapeutics to Present at the 2nd Annual LifeSci Partners
15 Jul 2021 //
GLOBE NEWSWIRE
Revolo Announces the Appointments of Marla S. Persky and Glen Giovannetti
01 Jul 2021 //
GLOBENEWSWIRE
Revolo Announces USFDA Approval of IND Application for Phase 2 Trial of ‘1104
23 Jun 2021 //
GLOBENEWSWIRE
Revolo and Northway Biotech Enter Manufacturing Partnership
11 Jun 2021 //
CONTRACTPHARMA
Revolo and Northway Biotech Enter Manufacturing Partnership
11 Jun 2021 //
CONTRACT PHARMA
Immune Regulation, taking two clinical programs to `reset` the immune system
21 Sep 2020 //
ENDPTS
